4D Molecular Therapeutics (FDMT) Other Accumulated Expenses (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Other Accumulated Expenses of $200000.0 for Q1 2026, up 24.22% year-over-year from $161000.0 in Q1 2025, and up 55.04% quarter-over-quarter from $129000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Other Accumulated Expenses (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Other Accumulated Expenses for 8 consecutive years, with $200000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 24.22% year-over-year to $200000.0; the TTM figure through Mar 2026 stood at $200000.0 (up 24.22% YoY), while the FY2025 annual figure was $129000.0, up 13.16% from the prior year.
- Other Accumulated Expenses rose to $200000.0 in Q1 2026 per FDMT's latest filing, from $129000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $748000.0 in Q2 2022 and bottomed at $45000.0 in Q1 2023.
- Historically, Other Accumulated Expenses has averaged $180411.8 across 5 years, with a median of $129000.0 in 2025.
- Annual changes were most pronounced in 2023 — Other Accumulated Expenses slumped 93.18% — and 2024, when it jumped 215.56%.
- 4D Molecular Therapeutics' Other Accumulated Expenses stood at $382000.0 in 2022, then tumbled by 72.77% to $104000.0 in 2023, then climbed by 9.62% to $114000.0 in 2024, then advanced by 13.16% to $129000.0 in 2025, then surged by 55.04% to $200000.0 in 2026.
- Business Quant data shows FDMT's Other Accumulated Expenses at $200000.0 in Q1 2026, $129000.0 in Q4 2025, and $108000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 124,000.00 |
| Mar 31, 2026 | 200,000.00 |
| Dec 31, 2025 | 129,000.00 |
| Sep 30, 2025 | 108,000.00 |
| Jun 30, 2025 | 102,000.00 |
| Mar 31, 2025 | 161,000.00 |
| Dec 31, 2024 | 114,000.00 |
| Sep 30, 2024 | 125,000.00 |
| Jun 30, 2024 | 96,000.00 |
| Mar 31, 2024 | 142,000.00 |
| Dec 31, 2023 | 104,000.00 |
| Sep 30, 2023 | 163,000.00 |
| Jun 30, 2023 | 51,000.00 |
| Mar 31, 2023 | 45,000.00 |
| Dec 31, 2022 | 382,000.00 |
| Sep 30, 2022 | 188,000.00 |
| Jun 30, 2022 | 748,000.00 |
| Mar 31, 2022 | 209,000.00 |
| Dec 31, 2021 | 1.77 Mn |
| Sep 30, 2021 | 420,000.00 |